Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Genitourinary 1Endocrine 1

Conditions

Carcinoma, Renal Cell 45Carcinoma, Hepatocellular 13Osteosarcoma 8Neoplasms 8Sarcoma 7Prostatic Neoplasms 7Neoplasm Metastasis 7Colorectal Neoplasms 7Sarcoma, Ewing 6Neuroendocrine Tumors 6Clear-cell metastatic renal cell carcinoma 6Carcinoma, Non-Small-Cell Lung 6Kidney Neoplasms 5Thyroid Neoplasms 4Carcinoma, Transitional Cell 4Carcinoma, Medullary 4Carcinoma 4Brain Neoplasms 4Urinary Bladder Neoplasms 3Urethral Neoplasms 3Ovarian Neoplasms 3Melanoma 3Endometrial Neoplasms 3Adrenocortical Carcinoma 3Wilms Tumor 2Urogenital Neoplasms 2Ureteral Neoplasms 2Triple Negative Breast Neoplasms 2Thyroid Cancer, Papillary 2Stomach Neoplasms 2

Interventions

zimberelimab 1pembrolizumab 1olaparib 1lutetium Lu 177 dotatate 1lanreotide 1fluorodopa F 18 1cabozantinib 1Sunitinib 1Random Allocation 1Octreotide 1Nivolumab 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoid Tumor × cabozantinib × 1 year × Clear all
NCT05263050 2026-05-22

Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors

Fox Chase Cancer Center

Phase 2 Recruiting
111 enrolled
EndocrineGenitourinaryNET

Clear-cell metastatic renal cell carcinoma, Carcinoid Tumor, Carcinoma, Renal Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡